Compare Crowdstrike Holdings Inc (CRWD) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Eli Lilly And Co — how do they compare? Crowdstrike Holdings Inc trades at $274.79 (market cap $269.31B), while Eli Lilly And Co trades at $1,177 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 3.9× Crowdstrike Holdings Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and Eli Lilly And Co for 93 Days on average.
| CRWD | LLY | |
|---|---|---|
Market Cap | $269.31B | $1.04T |
Volume | 9,381,560 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $278.86 | $1.28K |
52-Week Low | $87.56 | $799.57 |
Typical Hold Time | 97 Days | 93 Days |
Enterprise Value | $265.11B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $272.00, up 2.47% today and near its all-time highs, with strong technical momentum and bullish moving average signals. The company demonstrates impressive revenue growth, reaching $3.95 billion in 2025, though profitability remains volatile with a net income margin of -0.49%. Recent quarterly earnings have consistently beaten expectations, and analyst sentiment remains overwhelmingly positive with 76% buy ratings.
The outlook for CRWD remains favorable given strong cybersecurity demand and AI-driven growth opportunities, though elevated valuation multiples and competitive pressures present risks. Wall Street's consensus price target of $235.74 suggests potential downside from current levels, but continued execution on revenue growth and margin expansion could support further upside.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
